XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication ...Middle East

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell...

Hence then, the article about xpovio receives reimbursement approval in south korea for a second multiple myeloma indication was published today ( Monday 02/03/2026 - 03:34 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication )

Also on site :

• Makeup Artist Alexis Stone’s Jim Carrey Transformation Claim Divides the Internet
• NASDAQ: CRWV: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against CoreWeave, Inc. (CRWV)
• Colorado Buffaloes quarterback Dominiq Ponder dies